SCHEMBL3188265

SCHEMBL3188265

O=S(=O)(N[C@H](CO)Cc1ccc(OCc2ccccc2)cc1)c1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.61
BCL2L1 Q07817 3/20 0.53
MCL1 Q07820 3/20 0.53
ADAMTS4 O75173 5/20 0.52
MMP13 P45452 3/20 0.52
ADAMTS5 Q9UNA0 2/20 0.51
MMP2 P08253 2/20 0.51
POLB P06746 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NEK1 Q96PY6 2/20 0.49
GPR34 Q9UPC5 1/20 0.49
PTGES O14684 3/20 0.48
KCNH2 Q12809 2/20 0.48
MMP1 P03956 1/20 0.48
MMP9 P14780 1/20 0.48
MMP14 P50281 1/20 0.48
ADAM17 P78536 1/20 0.48
PGR P06401 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1287447 0.88 MMP2 (0.62) ADAMTS4ADAMTS5MMP2NEK1MMP9
SCHEMBL1287449 0.88 MMP2 (0.62) ADAMTS4ADAMTS5MMP2NEK1MMP9
SCHEMBL9513663 0.83 MMP2 (0.55) ARBCL2L1MCL1ADAMTS5MMP2
SCHEMBL14602239 0.82 MMP2 (0.79) ARBCL2L1MCL1ADAMTS4MMP13
SCHEMBL9512132 0.81 MMP2 (0.60) ADAMTS4ADAMTS5MMP2MMP9
SCHEMBL9512738 0.80 ALDH1A1 (0.57) ARMMP13ADAMTS5MMP2POLB
SCHEMBL1169469 0.78 MAPT (0.49) ARMMP2MMP1MMP9MMP14
SCHEMBL24242561 0.77 ADAMTS4 (0.65) ARADAMTS4MMP13ADAMTS5MMP2
SCHEMBL6325732 0.77 ADAMTS4 (0.65) ARADAMTS4MMP13ADAMTS5MMP2
SCHEMBL6325729 0.77 ADAMTS4 (0.65) ARADAMTS4MMP13ADAMTS5MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037778-A1 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide WYETH (US) 2007-02-15 US claimed
US-7166622-B2 Substituted phenylsulfonamide inhibitors of beta amyloid production WYETH (US) 2007-01-23 US claimed
US-20040006050-A1 Substituted phenylsulfonamide inhibitors of beta amyloid production WYETH (US) 2004-01-08 US claimed
US-20100120725-A1 Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production WYETH LLC (US) 2010-05-13 US disclosed
US-7671075-B2 Substituted phenylsulfonamide inhibitors of beta amyloid production WYETH (US) 2010-03-02 US disclosed
US-20070037778-A1 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide WYETH (US) 2007-02-15 US disclosed
US-7166622-B2 Substituted phenylsulfonamide inhibitors of beta amyloid production WYETH (US) 2007-01-23 US disclosed
US-20040006050-A1 Substituted phenylsulfonamide inhibitors of beta amyloid production WYETH (US) 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120725-A1 Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production APP, BACE1, PSEN1 AR 3289/4885BCL2L1 1596/4885MCL1 2822/4885
US-20070037778-A1 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide BACE1, APP, PSEN1 AR 2806/4885BCL2L1 872/4885MCL1 3072/4885
US-20040006050-A1 Substituted phenylsulfonamide inhibitors of beta amyloid production APP, BACE1, PSEN1 AR 3695/4885BCL2L1 1193/4885MCL1 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.